A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 [axitinib] In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion.

Trial Profile

A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 [axitinib] In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Axitinib (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met.
    • 14 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Planned end date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top